Tagged with Opinion

USA Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to ensure the safety of rare disease patients – many of them children – who are using CBD products for their…

AI Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be utilised within this process.   Companies should start by thinking of ways to leverage unified data sets and digital access points to create and deliver connected,…

Opinion Aditya Bhattacharji examines whether current healthcare models are truly fit for purpose and how healthcare is becoming a more politicised issue globally.   Globally, the healthcare sector is entering a lengthy period of heightened introspection. That process has been turbocharged by the resurgence of healthcare as a dominant social and…

Canada Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy this situation, Pamela Fralick of Innovative Medicines Canada outlines the strengths and weaknesses of the proposal on the table and…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019.     Due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant The cannabis industry…

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it.   45 percent of the patient population in neurology remains unserved – they either have no…

Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co.   Now that we have all this data,…

USA Jessica Federer, advisor at Hugo Health and one of the speakers at the upcoming FT US Pharma and Biotech Summit, discusses some of the key trends shaping the US pharma market, her predictions for the next year, and recent developments for women in pharma.   Recently, we have witnessed some…

USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…

Opinion Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug regulators and its potential to increase market capture and profitability.   RWE has the potential to expand the market size of a disease and accelerate market capture of a…

Opinion What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office of global management consultants Korn Ferry explain what they look for when hiring Mexico GMs, and outline some of the…